BioCryst Pharmaceuticals (BCRX) Posts Wider than Expected Q1 Loss
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.87 -6.8%
Financial Fact:
Interest expense: -1.47M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Interest expense: -1.47M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
BioCryst Pharmaceuticals (Nasdaq: BCRX) reported Q1 loss of ($0.29), $0.09 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $17.04 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Shotspotter (SSTI) Misses Q2 EPS by 19c; Offers Guidance
- TMC the metals company Inc. (TMC) Misses Q2 EPS by 8c
- Audioeye, Inc. (AEYE) Misses Q2 EPS by 28c; Offer Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
